A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)

Onychomycosis Clinical Trial

Official title:

An Investigator-Blinded Study Evaluating the Efficacy and Safety of Four Posaconazole Treatment Regimens With Placebo and Terbinafine in the Treatment of Onychomycosis of the Toenail

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00491764
• Other study ID #: P05082
• Status: Completed
• Phase: Phase 2
• First received: June 25, 2007
• Last updated: September 11, 2015
• Start date: June 2007
• Est. completion date: December 2008

Study information

• Verified date: September 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of oral administration of four dosing regimens of posaconazole relative to placebo and terbinafine, in the treatment of toenail onychomycosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 218
• Est. completion date: December 2008
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• The subject must meet ALL the criteria listed below for entry:

• Subject must be between 18 and 75 years of age inclusive, of either sex, and of any race;

• Subject must have distal subungual infection that affects approximately 25% to 75% of at least one great toenail, both clinically and mycologically diagnosed;

• Subject must have at least 2 mm of the proximal end of the target toenail free of infection;

• Subject must have a target toenail that is assessed as capable of growing approximately 1 mm/month, (eg, the subject needs to report cutting his or her toenails at least once per month);

• Subject must have liver function tests within 1.5 x the upper limit of normal (bilirubin and transaminases);

• Subject must have normal serum creatinine levels;

• Subject must be able to take study medication orally;

• Subject must have no history of current narcotic or alcohol addiction;

• Subject must be willing to give written informed consent and able to adhere to dose, procedures, and visit schedules;

• Woman of childbearing potential who is currently sexually active must agree to use a medically accepted method of contraception while receiving protocol-specified medication and for 30 days after stopping the medication. Methods include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed intrauterine device, oral or systemic hormonal contraceptive (plus an additional reliable barrier method), and surgical sterilization (eg, hysterectomy or tubal ligation).

Woman of child-bearing potential who is not currently sexually active must agree to use a medically accepted method of contraception should she become sexually active while participating in the study.

• Woman of childbearing potential must have a negative serum pregnancy test within 72 hours prior to start of study drug.

Exclusion Criteria:

• The subject will be excluded from entry if ANY of the criteria listed below are met:

• Subject with one or more of the following conditions on the target toenail:

• proximal subungual onychomycosis,

• white superficial onychomycosis,

• dermatophytoma or "yellow spike/streak",

• exclusively lateral disease,

• inability to become normal in the opinion of the investigator.

• Subject with psoriasis, severe moccasin-type tinea pedis requiring treatment, symptomatic interdigital tinea pedis, lichen planus, or other abnormalities that could result in a clinically abnormal nail;

• Subject with peripheral vascular disease or peripheral circulatory impairment;

• Subject with history of uncontrolled diabetes mellitus;

• Subject with known chronic or active liver disease;

• Subject with any known immunodeficiency;

• Subject with a family history of long QT syndrome;

• Subject with an electrocardiogram with QTc interval prolongation greater than 450 msec for males and 470 msec for females;

• Subject with potassium or magnesium lower than the lower limit of normal;

• Subject with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with study evaluations or optimal participation in the study;

• Subject who has received systemic antifungal therapy within 3 months or topical antifungal therapy applied to the foot or toenails within 1 month of study entry;

• Subject who has received radiation therapy, chemotherapy, and/or immunosuppressive drugs within 6 months of Randomization, and/or oral corticosteroids for >1 month within the 6 months of Randomization (exception: inhaled steroids);

• Subject using medications known to interact with azoles such as terfenadine, pimozide, quinidine, halofantrine, astemizole, alfentanil, cisapride, HMG-Co A (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors that are metabolized by CYP3A4, and ebastine, within 7 days prior to Randomization; and pravastatin within 14 days prior to Randomization;

• Subject using medications known to lower the serum concentration/efficacy of azoles including rifampin, rifabutin, cimetidine, carbamazepine, phenytoin, barbiturates, and isoniazid, 3 doses or more within 7 days prior to Randomization;

• Subject with a known sensitivity to azoles, POS and/or its excipients, terbinafine and/or its excipients;

• Subject who has been previously enrolled in this study or any other POS investigational trial;

• Subject known to have received treatment with investigational drugs within 30 days prior to enrollment into this study;

• Woman who is breastfeeding, pregnant, or intends to become pregnant;

• Subject who is part of the staff personnel directly involved with this study;

• Subject who is a family member of the investigational study staff.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Onychomycosis

Intervention

Drug:
• SCH 56592
Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
• SCH 56592
Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
• SCH 56592
Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
• SCH 56592
Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
• Terbinafine
Terbinafine 250 mg QD for 12 weeks.
• Placebo
Placebo for 24 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Cure of Onychomycosis at Week 48.	Complete cure is defined as negative mycology (negative culture and KOH [potassium hydroxide]) and 0% nail involvement (defined as absence of onycholysis and subungual hyperkeratosis).	Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48	No
Secondary	Effective Treatment of Onychomycosis at Week 48.	Effective treatment is defined as negative mycology (negative culture and KOH) and either 0% nail involvement or >5 mm growth of unaffected nail	Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48	No
Secondary	Treatment Success of Onychomycosis at Week 48	Treatment success was defined as negative mycology (negative culture and negative KOH) and =<10% nail involvement.	Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48	No